Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05711082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REALITY MONITORING AND DOPAMINE

Study acronym: MORDOR
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 30, 2026 to Jan 15, 2027
    • Study completion date: Dec 31, 2026 to Feb 28, 2027
    • Study title expanded, about 2 words
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to Jan 15, 2024
    • Study sites: 0 to 1
    v3
  4. Start date: Apr 1, 2023 to Jul 1, 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Reality-monitoring characterizes the ability to determine whether information was perceived in the environment or only imagined . Impaired reality-monitoring abilities have been associated with hallucinations in patients with schizophrenia and patients with Parkinson's disease. The investigators hypothesize a link between dopaminergic (DA) transmission and reality-monitoring.
Trial Details
NCT Number NCT05711082
Lead Sponsor Hôpital le Vinatier
Conditions
(from sponsor)		 Neurosciences
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov